Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H24F2N2O3 |
Molecular Weight | 438.4665 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC(=O)C1=CN(CC(C)(C)C2=C1NC3=C2C=CC=C3)C(=O)C4=CC=C(F)C(F)=C4
InChI
InChIKey=INASOKQDNHHMRE-UHFFFAOYSA-N
InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3
Molecular Formula | C25H24F2N2O3 |
Molecular Weight | 438.4665 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19159286Curator's Comment: Description was created based on several sources, including
http://www.pharmacodia.com/yaodu/html/v1/chemicals/ba3c5e7b68dbdb900c4ee701df6cd6b5.html
http://adisinsight.springer.com/drugs/800025892
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19159286
Curator's Comment: Description was created based on several sources, including
http://www.pharmacodia.com/yaodu/html/v1/chemicals/ba3c5e7b68dbdb900c4ee701df6cd6b5.html
http://adisinsight.springer.com/drugs/800025892
Turofexorate Isopropyl (XL335) is a potent, selective, and orally bioavailable FXR agonist. Binds to the ligand-binding domain (LBD) of human FXR. Turofexorate Isopropyl resides in a predominately hydrophobic pocket with only a few polar atoms making contact with WAY-362450. Turofexorate Isopropyl promotes transcription of the human BSEP, human SHP, and mouse IBABP genes utilizing reporter constructs with EC50 of 17, 230, and 33 nM, respectively in promoter assays. Turofexorate Isopropyl had been in phase I clinical trials for the treatment of hyperlipidemia. This compound was originally discovered by Exelixis Pharmaceuticals, then licensed to Wyeth (now a wholly-owned subsidiary of Pfizer). However, the studies were discontinued.
Originator
Sources: http://adisinsight.springer.com/drugs/800025892
Curator's Comment: # Exelixis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2047 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19159286 |
4.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00499629
capsule, single oral doses from 10 mg to 450 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19159286
Turofexorate Isopropyl (WAY-362450) at concentration of 1 μM significantly induces mRNAs encoding for BSEP, SHP, and IBABP in human cell cultures to 13-, 2-, and 20-fold, respectively. Turofexorate Isopropyl at concentration of 1 uM suppresses interleukin-6-induced CRP expression in human Hep3B hepatoma cells, and the inhibitory effect is attenuated when knockdown of FXR by short interfering RNA.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:23:09 GMT 2023
by
admin
on
Sat Dec 16 17:23:09 GMT 2023
|
Record UNII |
S6KDM312I5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29703
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12719
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
PRIMARY | |||
|
629664-81-9
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
PRIMARY | |||
|
S6KDM312I5
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
PRIMARY | |||
|
10026128
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
PRIMARY | |||
|
DTXSID90978825
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
PRIMARY | |||
|
9095
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
PRIMARY | |||
|
UU-51
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
PRIMARY | |||
|
300000034455
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
PRIMARY | |||
|
C81536
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
PRIMARY | |||
|
CHEMBL454138
Created by
admin on Sat Dec 16 17:23:09 GMT 2023 , Edited by admin on Sat Dec 16 17:23:09 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|